Clinical features and outcomes of<i>ALK</i>rearranged non‐small cell lung cancer with primary resistance to crizotinib
Di Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Du(Harbin Medical University), Xuezhi Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shan Li(State Key Laboratory on Integrated Optoelectronics), Yan Zhang(Xinjiang Medical University), Li Liang(Peking University Third Hospital), Zhaohui Zhang(Peking University), Mengzhao Wang(Peking Union Medical College Hospital), Tao Xin(Harbin Medical University), Yan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongge Liang(Guangdong University of Technology)
Cited by 6
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Room temperature NO 2 gas sensor based on porous Co 3 O 4 slices/reduced graphene oxide hybrid
|Sensors and Actuators B Chemical|2018|203
Comprehensive analysis of prognostic immune‐related genes in the tumor microenvironment of cutaneous melanoma
|Journal of Cellular Physiology|2019|111
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
|OncoTargets and Therapy|2020|111
PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment
|Future Oncology|2017|65